Ontology highlight
ABSTRACT: Purpose
We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody-drug conjugate (ADC) PF-06647020/cofetuzumab pelidotin (NCT02222922).Patients and methods
Patients received PF-06647020 intravenously every 3 weeks at 0.2-3.7 mg/kg or every 2 weeks at 2.1-3.2 mg/kg, in sequential dose escalation, following a modified toxicity probability interval method. In dose expansion, pretreated patients with advanced, platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC) received PF-06647020 2.8 mg/kg every 3 weeks.Results
The most common, treatment-related adverse events for PF-06647020 administered every 3 weeks were nausea,
SUBMITTER: Maitland ML
PROVIDER: S-EPMC9401513 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature